Natco pharma launches epilepsy drug Brivaracetam in India
NATCO's BRECITA tablets will be available in two strengths of 50 mg and 100 mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively.
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced the launch of Brivaracetam tablets under brand BRECITA in India. Brivaracetam is indicated towards treatment of epilepsy. Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact. NATCO's BRECITA tablets will be available in two strengths of 50mg and 100mg at...
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced the launch of Brivaracetam tablets under brand BRECITA in India.
Brivaracetam is indicated towards treatment of epilepsy.
Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact.
NATCO's BRECITA tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of INR 25/- and INR 35/- per tablet respectively.
Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd